As previously announced, each debenture consists of $1,000 aggregate principal amount of secured, non-transferable, convertible, redeemable debentures (the “Debentures”), maturing on December 31, 2019 (the "Maturity Date”) and bear interest at a rate of 12% per annum. The principal amount of the Debentures is convertible into common shares of the Company (“Common Shares”) at the option of the holder at a price of $0.055 per Common Share.

Each debenture will consist of $1,000 aggregate principal amount of secured, non-transferable, convertible, redeemable debentures (the “Debentures”). The Debentures will mature on December 31, 2019 (the "Maturity Date”) and bear interest at a rate of 12% per annum.

Enrollment rates have increased substantially over the past several weeks, with an additional nine (9) patients enrolled and treated under the Company’s CLI clinical trial protocol. A total of thirty-three (33) patients have been treated to date, representing over one third of the total trial enrollment goal. The Company currently has twelve (12) trial sites open, of which eleven are located in the United States and one in Vancouver, Canada, that are actively screening patients for enrollment in the study. The Company has additional clinical trial sites starting up in Canada and the United States.

OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D, Ph.D. has been appointed the Company’s President and Chief Medical Officer. Dr. Jacobs previously acted as a medical consultant to the Company. Dr. Jacobs takes over the role of President from Kyle Makofka who remains as the Company’s Chief Executive Officer.

UC Davis Medical Center brings state-of-the-art vascular care to patients throughout Central and Northern California. The Division of Vascular Surgery at UC Davis Medical Center has grown to become the largest vascular specialty group in the region.

OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, is pleased to announce that it has submitted an application with the US Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (”ODD”) status for its lead product ACP-01 for the treatment of critical limb ischemia (“CLI”).

NEW YORK, NY / ACCESSWIRE / January 10, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”). In addition, the Company is pleased to provide an update on patient enrollment in the trial. Medical University of South Carolina is located in Charleston, South Carolina, USA with Dr. Thomas E. Brothers, MD as the principal investigator. Dr. Brothers is a vascular surgeon who focuses on management of circulation and peripheral vascular disease and has been recognized as one of America’s top surgeons and best doctors since 2003. Founded in 1824, the Medical University of South Carolina (“MUSC”) educates and trains more than 3,000 students and 700 residents in six colleges and has nearly 13,000 employees, including approximately 1,500 faculty members. MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the NCI-designated Hollings Cancer Center, a Level I trauma centre and South Carolina’s only transplant center.

NEW YORK, NY / ACCESSWIRE / November 21, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

OTCQB: HMTXF) is pleased to provide the following update on its research and development activities. Further to the Company’s press release dated November 8, 2018 where it discussed research and development initiatives and refinements to its manufacturing process, the Company is pleased to announce it has made additional findings surrounding its overall technology platform and initiation of R&D work on NCP-01, another one of its product pipeline candidates. As disclosed in its recent press release, the Company has been furthering its research and development (“R&D”) initiatives with a focus on optimizing the manufacturing process of ACP-01, with an underlying focus on continuing to expand the potential of the Company’s technology platform.

NEW YORK, NY / ACCESSWIRE / October 25, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...